Rithim Biologics® is developing technologies utilizing gene therapy for reduction; prevention; and/or treatment of tachycardias (fast heart rates).  Our current focus is on:

  • Development of KCNH2-G628S gene therapy for post-operative atrial fibrillation (POAF) in patients undergoing cardiac bypass (CABG) and heart valve surgeries.
  • Development of proprietary instrumentations to facilitate efficacious delivery of a range of gene therapies for the treatment of cardiac tachyarrhythmias.